Cargando…
Beyond Traditional Structure-Based Drug Design: The Role of Iron Complexation, Strain, and Water in the Binding of Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylase 2
[Image: see text] A combination of structure-based drug design and medicinal chemistry efforts led us from benzimidazole-2-carboxamide with modestly active hypoxia-inducible factor prolyl hydroxylase 2 inhibition to certain benzimidazole-2-pyrazole carboxylic acids that were more potent as well as o...
Autores principales: | Bembenek, Scott D., Venkatesan, Hariharan, Peltier, Hillary M., Rosen, Mark D., Barrett, Terrance D., Kanelakis, Kimon C., Palomino, Heather L., Brondstetter, Theresa I., Mirzadegan, Taraneh, Rabinowitz, Michael H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2019
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547624/ https://www.ncbi.nlm.nih.gov/pubmed/31179408 http://dx.doi.org/10.1021/acsomega.9b00199 |
Ejemplares similares
-
Assessing the Carcinogenicity of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, in Rodents
por: Kowalski, Heather, et al.
Publicado: (2023) -
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism
por: Ogawa, Chie, et al.
Publicado: (2023) -
Hypoxia inducible factor prolyl hydroxylases in inflammatory bowel disease
por: Lun, Jie, et al.
Publicado: (2023) -
Neuroprotective Effect of HIF Prolyl Hydroxylase Inhibition in an In Vitro Hypoxia Model
por: Savyuk, Maria, et al.
Publicado: (2020) -
Hypoxia-inducible factor prolyl hydroxylase inhibitors in kidney transplant recipients
por: Ogata, Masatomo, et al.
Publicado: (2022)